Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
150M PLX-PAD · 1 trial · 2 indications
Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.
| Arm | Type | Description |
|---|---|---|
| 150M PLX-PAD | EXPERIMENTAL | Single course, multiple IM injections |
| 300M PLX-PAD | EXPERIMENTAL | Single course, multiple IM injections |
| Placebo | PLACEBO_COMPARATOR | Single course, multiple IM injections |
| Name | Type | Description |
|---|---|---|
| 150M PLX-PAD | BIOLOGICAL | Single course, multiple IM injections |
| 300M PLX-PAD | BIOLOGICAL | Single course, multiple IM injections |
| Placebo | BIOLOGICAL | Single course, multiple IM injections |
Inclusion Criteria: 1. Male or female subjects between 50 to 75 years of age 2. Scheduled THA 3. ASA Score ≤ 3 4. Signed written informed consent Exclusion Criteria: 1. Muscle diseases 2. Severe neurological diseases 3. Opioid long term medication 4. Pain chronification \> stadium II of Gerbersha...
150M PLX-PAD is an investigational therapy being studied for use in total hip arthroplasty, specifically for the regeneration of injured gluteal musculature after the procedure. It is a monoclonal antibody developed by Pluri Inc. and is currently in Phase 1 clinical development.
150M PLX-PAD is a monoclonal antibody, but its specific molecular target has not been disclosed. The therapy is being investigated for its potential to regenerate injured gluteal musculature following total hip arthroplasty, based on a completed Phase 1 clinical trial.
150M PLX-PAD is developed by Pluri Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLUR. The company is conducting clinical research on this therapy for the regeneration of injured gluteal musculature after total hip arthroplasty.
150M PLX-PAD is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed, and the therapy remains under investigation for its safety and efficacy.
150M PLX-PAD has one completed clinical trial registered as NCT01525667, titled 'Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty.' This Phase 1 study enrolled 20 participants in Germany and was randomized, double-blind, and placebo-controlled.
150M PLX-PAD is a specific dose or formulation of the investigational therapy PLX-PAD, developed by Pluri Inc. The clinical trial NCT01525667 evaluated intramuscular injections of PLX-PAD for muscle regeneration after total hip arthroplasty, and 150M refers to the dose level studied.